| Georgina H. Kilfoil |
Georgina H. Kilfoil is currently the Vice President-Clinical Operations at ATAI Life Sciences NV since 2020. She previously worked as the Vice President-Alliances & Project Management at Peninsula Pharmaceuticals, Inc. from 2004 to 2005, and as the SVP-Product Development & Project Management at Anthera Pharmaceuticals, Inc. from 2010 to 2013. From 2015 to 2019, she served as the Chief Development Officer at Benitec Biopharma Ltd. Kilfoil completed her undergraduate degree at the University of Bristol and earned an MBA from the Australian Graduate School of Management. |
| Kevin Craig |
Kevin Craig is currently the Chief Medical Officer at ATAI Life Sciences NV. Previously, he worked as the Senior Director-Neuroscience at Labcorp Drug Development, Inc. and as the Head-Early Clinical Development at Jazz Pharmaceuticals, Inc. Dr. Craig holds a graduate degree from the University of Cambridge and the University of the Witwatersrand. |
| Samantha Bender |
Samantha Bender is currently working as a Senior Project Manager-Research & Development at ATAI Life Sciences NV since 2021. Prior to this, she worked as a Senior Program Manager at Agios Pharmaceuticals, Inc. Ms. Bender completed her undergraduate and graduate degrees from Northeastern University. |
| Anne Johnson |
Ms. Anne Johnson, CPA, is a Chief Financial & Accounting Officer at ATAI Life Sciences NV. Ms. Johnson was previously employed as a Controller by Aruvant Sciences, Inc., a Corporate Controller by Chimerix, Inc., and a Vice President-Finance by Xanodyne Pharmaceuticals, Inc. She received her undergraduate degree from The University of North Carolina at Wilmington. |
| Chris Lee |
Chris Lee is currently working as the Director of Information Technology at ATAI Life Sciences NV since 2021. Prior to this, he worked as the Director of Information Technology Operations at the American Academy of Orthopaedic Surgeons and as the Director of Information Technology & Infrastructure at PharMEDium Services LLC. Mr. Lee completed his undergraduate degree from Lewis University. |
| Rolando GutÃerrez-Esteinou |
Presently, Rolando GutÃerrez-Esteinou occupies the position of Chief Medical Officer at ATAI Life Sciences NV.
He previously occupied the position of Senior Vice President-Medical & Pharmacovigilance at Aptinyx, Inc., VP-Clinical Development & Pharmacovigilance at Marinus Pharmaceuticals, Inc., Executive Director & VP-Global Therapeutic at Takeda Pharmaceutical Co., Ltd. and Vice President-Global Therapeutic Area at Labcorp Clinical Development GmbH.
He received a doctorate from Universidad Nacional Autónoma de México. |
| Srinivas G. Rao |
Srinivas G. Rao was the founder of Kyalin Biosciences, Inc. (founded in 2011) where he served as the Chief Executive Officer from 2011 to 2013. He is also the founder of ATAI Life Sciences AG (founded in 2018) where he currently holds the position of Chief Scientific Officer. Additionally, he is the founder of Kures, Inc. (founded in 2019) and ATAI Life Sciences NV (founded in 2018), where he currently holds the positions of Chief Scientific Officer and Chief Executive Officer respectively. Dr. Rao is also the founder of IntroSpect Digital Therapeutics, Inc...Dr. Rao's current job(s) include being the Chief Executive Officer at EntheogeniX Biosciences, Inc. since 2019. He is also a Director at Perception Neuroscience, Inc., a Member of the Society For Neuroscience, and a Member of the American College of Neuropsychopharmacology. Dr. Rao's former job(s) include being the Chief Scientific Officer & Director-Science at Cypress Bioscience, Inc. from 2000 to 2009. He was also a Non-Executive Director at Bionomics Ltd. from 2020 to 2021, a Director at IntelGenx Technologies Corp. from 2021 to 2023, and the Chief Medical Officer & Senior Vice President at Assertio Therapeutics, Inc. from 2014 to 2017. He has also held positions at Travere Therapeutics, Inc., Axial Therapeutics, Inc., and GABA Therapeutics, Inc.Dr. Rao's education history includes obtaining a doctorate degree from Yale School of Medicine and Yale Graduate School of Arts & Sciences. |
| Christian Berthold Angermayer |
Christian Berthold Angermayer founded Alnylam Europe AG in 2000, ATAI Life Sciences AG in 2018, Presight Capital Management Co LLC in 2018, and various other companies. Mr. Angermayer also founded Apeiron Investment Group AG, Samara Asset Group Plc, North American Council For Online Learning Ltd., and various other companies. Mr. Angermayer also currently works at Frontier Acquisition Corp., as Chief Executive & Director, Blackrock Microsystems, Inc., as Director, Co-Investment Fund 4 A Sub-Fund of Apeiron Sicav Ltd., as Director, and various other companies. Mr. Angermayer also formerly worked at Deutsche Maklerservice AG, as Director-Supervisory Board from 2004 to 2007, C-QUADRAT Investment AG, as Director-Supervisory Board from 2006 to 2008, VCH Investment Group AG, as Director-Management Board from 2005 to 2006, and various other companies. Mr. Angermayer received his undergraduate degree from the University of Bayreuth. |
| Glenn Short |
Glenn Short is currently the Chief Executive Officer at EmpathBio, Inc. and Atai Therapeutics, Inc. He is also the Chief Scientific Officer at ATAI Life Sciences NV starting in 2025. Previously, he held the position of VP-Research & Translational Development at Flex Pharma, Inc. Dr. Short obtained his undergraduate and doctorate degrees from the University of Virginia. |
| Frank Stegert |
Frank Stegert is the founder of 99chairs GmbH, which was founded in 2014. He is currently working as VP-Investment Management & Operations at ATAI Life Sciences AG since 2021, and also holds the position of Vice President-Investment Management at ATAI Life Sciences NV. He previously worked as Director at IntelGenx Technologies Corp. from 2021 to 2023, and as Senior Vice President & Head-Fund Banking at Deutsche Handelsbank AG from 2019 to 2020. Mr. Stegert completed his undergraduate degree from Technische Universität München. |
| Gerd G. Kochendoerfer |
Gerd G. Kochendoerfer is currently the Chief Operating Officer at NFlection Therapeutics, Inc. and ATAI Life Sciences NV. Previously, he held positions as the Senior Director-Drug Development at FibroGen, Inc., Director-Research & Development at Gryphon Therapeutics, Inc., Vice President-Pharmaceutical Development at Assertio Therapeutics, Inc., and Senior Vice President & Head of Operations at PellePharm, Inc. Dr. Kochendoerfer obtained a doctorate degree from the University of California, Berkeley. |
